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Owing to problems in making high affinity human mAbs, thereis interest in the
therapeutic application of chimeric antibodies in which either the V domains orjust
the hypervariable regions of rodent mAbs have been used to replace the equivalent
parts of a human antibody (1, 2, and references therein). Whereas xenogeneic anti-
bodies are highly immunogenic in man (see reference 3 for references), little is known
about the immunogenicity of chimeric antibodies. It is unclear to what extent a par-
ticular V domain is characteristic of the species from which it originates, and there-
fore, whether a response will be elicited by an antibody in which only the V region
is foreign. If there is such an antiidiotypic response, to what extent is it enhanced
by linkage to foreign C domains? Here, we describe experiments carried out in the
mouse that address these questions.
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Materials and Methods
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Mice and Immunizations.
￿
Mice were from Olac, Bicester, UK, or National Institute for
Medical Research, Mill Hill, UK. Prebleed sera were taken from 6-8-wk-old females (six
per group), which were then injected intraperitoneally with the relevant antibody (40 Ag)
in CFA. Serum was taken 30 d later, and the animals were boosted intraperitoneally with
the same antibody (40 Rg) in IFA; serum was taken after a further 10 d. For injection with
cell-bound antibody, spleen cells from F, mice were conjugated with 4-hydroxy-3-nitro-
phenacetyl (NP)-kephalin (4); mice were immunized intravenously with 5 x 106 syngeneic
NP-spleen cells mixed with 40,ugof anti-NP antibody. The boost (day 30) was the same as
the primary immunization.
AntibodiesandImmunoassays.
￿
Antibodies were purified by affinity chromatography (4) from
the supernatants ofcellsof the J558L plasmacytoma (which secretes X L chains) transfected
with plasmids directing the synthesis ofthe appropriate antibody H chain. The H chain genes
for HuVNP-Hu-y2, HUVNP-Moy2bb, and MOVNP-Moy2bb were assembled by inserting C
exon fragments (7.2-kb Hind III-Barn HI fragment for human y2 [described in reference
4]; 4.2-kb Eco RI-Bgl II fragment for mouse y2b' [ref. 5]) into the PSVVNP vector or a
derivative containing the HuVNP V domain (2). Other transfectants have been described (1,
2, 4).
Antibody responses were measured by ELISA. Serum dilutions were incubated in microtitre
plates coated with the relevant IgH, X anti-NP antibody. Bound antiantibodies were detected
using biotinylated anti-mouse K antiserum and horseradish peroxidase coupled to streptavidin.
Immune sera had less than threefold the prebleed titre of residual X-bearing anti-NP anti-
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body, as well as ofantibodies reacting with either mouse IgM, X myeloma protein, or purified
X L chains.
Results and Discussion
The response was compared of mice injected with one of three antibodies . The
most xenogeneic antibody (HuVNP-Hu-y2) is composed of a human -y2 C region
linked to aV domain that has the framework residues ofthehumanNEWmyeloma
protein (Fig . 1). A chimeric derivative (inwhich only theV region frameworks are
human) was created by substituting the human C-y2 by the C-y2b ofC57BL/6 mice
to yield HuVNP-Moy2bb . In MOVNP-Mo-y2bb (the syngeneic antibody), the entire
Vdomain is ofmouse origin, the foreign framework residues having been substituted
by mouse sequences. All the antibodies contain a mouse A L chain, as well asV
hypervariable region sequences derived from a mouse antibody specific for NP
Groups of(C57BL/6 x BALB/c)Fi mice were immunized intraperitoneally with
the three antibodies in CFA . The mice made a strong primary and secondary re-
sponse to the most xenogeneic antibody, a reduced yet nevertheless considerable re-
sponse to the chimeric antibody, but no detectable response to the syngeneic anti-
body (Fig. 2 A) . In the mice immunized with the HuVNP-Huy2, a large proportion
ofthe response was directed against thehuman -y2 C region, as witnessed by binding
inhibition assays using a human IgG2 myeloma protein; much less inhibition was
given by an antibody (HuVNP-Hue) whoseH chain is composed of the HuVNPV
domain linked to human Cc (Fig. 3 A, I). The anti-V region response elicited by
the xenogeneic antibody HuVNP-Huy2 was measured using a HuVNP-Hue coat ; it
was of a similar order to that elicited by HuVNP-Mo-y2bb (Fig . 3 B) . Thus, a con-
siderable proportion of the response to the xenogeneic antibody was directed against
theV region ; this antiidiotypic response was not diminished by using the chimeric
antibody with self C regions .
The antiidiotypic response in the mice immunized with either HuVNP-Huy2 or
HuVNP-Mo,y2bb was not exclusively directed against the human frameworks of the
immunizing antibody, although these are the only foreign determinants in theV
domain . The mice contained a significant titre ofantibodies that recognized MOVNP
(Fig . 3, A and B) . A more direct demonstration that it is possible to elicit an anti-
body response to syngeneic V domains is provided by immunizing mice with
MOVNP-Huy2 (Fig. 3 B) . Thus, the mouse can make a response to its own V do-
mains, and probably to the hypervariable regions themselves . However, this response
is not elicited unless the administered antibody contains some foreign determinants .
As a better system to mimic the use ofmAbs directed against tumor cell surface
FIGURE 1 .
￿
Structure of anti-
bodies. (A) Antibodies used for
immunization . (B) Antibodies
used for testing the specificity of
the responses. The open andfilled
bats denote sequences of mouse
and human origin, respective-
ly. (x) Amino acid positions
at which MoVNP-Moy2b4 and
MoVNP-Mo,y2bb differ.BRLJGGEMANN ET AL .
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FIGURE 2 .
￿
Responses to administered antibodies . (A)
Responses to antibodies emulsified in Freund's . (B) Re-
sponses to antibodies bound to syngeneic spleen cells .
Bars in the histogram give the serum dilution from in-
dividual mice that yield half-maximal binding to the im-
munizing antibody immobilized on theplate. Thus, sera
from MoVNp-Moy2bb-immunized mice were tested on
an MOVNp-Moy2bb coat, etc . Lightly crosshatched bars
give titres for the primary response ; stronger cross-
hatching indicating the increase in the secondary re-
sponse. A bar indicates the titres obtained from the
preimmune sera. Where therewasno significantdiffer-
ence between the primaryandsecondaryresponses, only
the secondary is depicted .
FIGURE 3.
￿
Specificity ofthe antiantibodies. (A)
Binding inhibition assays. The bindings of an-
tiantibodies in aserum dilution from individual
mice hyperimmunized with (1)HUVNP-Huy2 in
Freund's, (11) HuVNp-Moy2bb in Freund's, or
(111) cell-bound HuVNp-Huy2 were tested on a
coat oftheimmunizing antibody in the presence
of various concentrations of competitor. The re-
sult is given as the percentage binding relative
to that obtained in the absence ofinhibitor . Inhi-
bition assays shown are for individual mice but
are representative of the three in each group
tested . (B) Direct binding of sera from mice
hyperimmunized with HuVNp-Huy2, HuVNp-
Mcy2bb, or MoVNp-Huy2 antibody in Freund's
to a MoVNp-Hue or HuVNp-Hue coat ; binding
could not be inhibited with a human IgE myelo-
ma protein . Bars for individual mice titred on
MoVNp-Hue are aligned with bars for the same
mice titred on HuVNp-Hue.
markers, mice were challenged with syngeneic spleen cells to which antibody had
been bound . While the responses were considerably weaker than to the antibodies
administered in CFA, the cell-bound xenogeneic and chimeric antibodies neverthe-
less elicited a clear response with the major part of the response to HUVNP-Huy2
being directed against the C region (Figs . 3 A and 2 B) . Within the variation from
individual animals, there was no clear difference in the immunogenicity of the
xenogeneic and chimeric antibodies . The contrast between these results and those
obtained using Freund's might be accounted for by the fact that mouse IgG2b, but
not human IgG2, binds to some mouse Fc receptors (6) .
Although administration of a syngeneic antibody need not elicit an antiantibody2156
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FIGURE 4.
￿
Allogeneic respon-
ses. (A) The response ofC57BL/
6, BALB/c, C57BL/Ks, and
C57BL/Ks.A-20 mice to immun-
ization intraperitoneally with
MOVNP-MOry2bb antibody in
Freund's . (B) Binding inhibition
assay of the antiantibody re-
sponse in one of the MOVNP-
Moy2bb -immunized BALB/c
mice. Ofthree other mice test-
ed, two gave curves similar to
those presented, whereas one
showed a greater degree of in-
hibition by MOVNP-y2b b than
by MOVNP-Hue .
response, polymorphism within the human population may lead to responses even
to wholly human antibodies . To compare the magnitude of such an allotyppc re-
sponse with the response mounted against foreignV region frameworks, MOVNP-
Mo,y2bb was injected into both C57BL/6 (the strain from which the antibody
originates) and BALB/c mice . Unlike C57BL/6, the BALB/c mice made a strong
response against MOVNP-Moy2bb, recognizing bothV andC domains (Fig . 4A) .
Although immune response genes could well play a role (7), the difference in the
response obtained with the C57BL/6, BALB/c, and Ft mice is likely to be due to
the difference in Igh haplotypes . This was confirmed by comparing the responses
of C57BL/Ks (H2d, Ighb) with C57BL/Ks.A-20 (H2d, Igh') mice (Fig. 4 B) .
Thus, an antibody with both foreignC domains and foreignV frameworks was
strongly immunogenic, eliciting a response that was largely directed against theC
region but with a substantial component against theV . In a chimeric derivative (in
which only theV region frameworks are foreign), the anti-C responsewasabolished
but the response to theV remained andwasunattenuated . While allforeign frame-
work sequences maynot prove equally immunogenic, the results indicate that, short
of administering an autologous antibody, therapeutic applications should make use
of antibodies in which care has been taken to reduce theV region immunogenicity.
However, the immunogenicity of antibodies in which the hypervariable regions are
the sole foreign determinants is an unknown quantity and is an important focus
for further research . Extrapolating to therapy in man, the results caution that, even
with wholly human antibodies, problems may be encountered with allogeneic re-
sponses directed against both theV and theC. Ultimately, it may prove advisable
not just to usehumanized antibodies, but to use antibodieswhose allotype is matched
to that of the patient .
Summary
Mice were immunized with model xenogeneic (both theV frameworks and the
C domains ofhuman origin), chimeric (justVH frameworks human), or self anti-
bodies, and the antiantibody responses were dissected. Only the self antibody did
not elicit aresponse .Astrong responsewas elicited by themost xenogeneic antibody
with -90% against the C and -10%O against theV . The anti-V response was notBRiJGGEMANN ET AL.
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attenuated in the chimeric antibody, demonstrating that foreign VH frameworks can
be sufficient to lead to a strong antiantibody response. The magnitude of this
xenogeneic antiV response was similar to that of the allotypic response elicited by
immunizing mice of the Igha allotype with an Ighb antibody. Thus, although
chimerization can diminish antiantibody responses, attention should be paid both
to V region immunogenicity and to polymorphism.
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